Tagged with R

IDS Distribution IDS Distribution is part of an Asian, globe spanning Distribution Company. How does being part of a large, regionally specialized player help IDS Distribution in Indonesia? The company’s regional presence is quite strong. When I first began working at IDS Distribution, I wasn’t sure about the right way to grow…

Pfizer South Korea Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are things in Korea’s pharmaceutical industry 15 years since you first left it? South Korea has evolved dramatically over the last…

Bayer Indonesia Many multinational companies have chosen to forgo establishing production facilities in Indonesia or have even shuttered their facilities, as did Janssen-Cilag. With the recent 10/10 decree, it seems the environment may become even more hostile to foreign companies. Why has Bayer always had such a strong commitment to the country…

Solvay Pharma Indonesia While the level of sales for pharmaceutical products is plunging in the US and Europe one of the core pillar of Solvay’s strategy is to have a stronger focus on the Asia Pacific region, which for the Pharmaceutical segment represents still less than 9% of the sales. In this respects,…

Boryung Pharmaceutical Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you tell us, as the founder, about this notable achievement? Boryung just celebrated in 2007 its 50th anniversary, since it was…

Korea National Enterprise for Clinical Trials Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in Korea began in the 1990s, but at that time they were limited to either local studies for domestically developed compounds…

TEVA Germany The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process continued with the recent acquisition of AWD Pharma in 2008. What as the impact of such acquisitions in your German…

Anugerah Corporation The development of the Local Pharmaceutical industry companies has gone through rough times, competing from the very beginning with MNCs and going through the economic shock in the 90’s. In this period while many companies couldn’t cope with the market competition, Anguerah Corporation succeeded in positioning itself as one of…

Euticals group After a long experience at BMS, you are since 2002 at the head of Euticals- a well established group consisting of four entities (Euticals, Ambrosia, Prochisa and Pro.Bio.Sint), each of them developing and producing Active Pharmaceutical Ingredients (APIs) by different processes. To begin, could you give us an overview of…

Parexel International Italy Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and which opportunities does the local environment provide to the group? The high number of clinical trials conducted in Italy every…

AstraZeneca South Korea You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector from a Chinese perspective? My exposure to Korea while in China was much more on the drug discovery and development…

Bausch & Lomb Germany With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities that no other company could thanks to its own transformations and special needs. Since Bausch&Lomb changed ownership in 2007, our…